On Disease Modifying and Neuroprotective Treatments for Parkinson's Disease: Physical Exercise

Ruiz, Pedro; Piudo, Rosario Luquin; Castrillo, Juan Carlos Martínez

doi:10.3389/fneur.2022.938686

Cited by 7 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meta-analyses of longitudinal observational studies show aerobic and other forms of exercise to be associated with reduced risk of dementia, and may even have an effect in preventing dementia in adults with normal cognition and mild cognitive impairment [12] . To date, physical activity is the only disease-modifying intervention for idiopathic Parkinson’s disease, with evidence for improving both motor and executive function [13] , [14] . Exercise has been shown to alleviate depressive symptoms, likely by promoting neurotrophic factors [15] .…”

Section: Physical Activity In Fnd and Comorbid Disordersmentioning

confidence: 99%

Functional neurological disorder, physical activity and exercise: What we know and what we can learn from comorbid disorders

Boylan,

Dworetzky,

Baslet

et al. 2024

Epilepsy & Behavior Reports

View full text Add to dashboard Cite

Section: Physical Activity In Fnd and Comorbid Disordersmentioning

confidence: 99%

Functional neurological disorder, physical activity and exercise: What we know and what we can learn from comorbid disorders

Boylan,

Dworetzky,

Baslet

et al. 2024

Epilepsy & Behavior Reports

View full text Add to dashboard Cite

“…8 Even though they are still under investigation, disease-modifying treatments are assumed to maximize benefits if introduced at an early-stage of the disease, before the apparition of the motor symptoms. 9,10,11 Given the widespread peripheral changes observed early in PD, using easily accessible peripheral tissues for biomarker discovery is highly promising. Indeed, the involvement of multisystem inflammation in PD pathophysiology has been suspected for some time with the first report dating back to 1988 when McGeer et al 12 noted microglial activation in the substantia nigra of PD postmortem brains.…”

Section: Introductionmentioning

confidence: 99%

Mapping the peripheral immune landscape of Parkinson’s disease patients with single-cell sequencing

Moquin-Beaudry,

Andriamboavonjy,

Audet

et al. 2024

Preprint

View full text Add to dashboard Cite

Parkinson's Disease (PD) is widely recognized for its impact on the central nervous system. Recent breakthroughs underscore the crucial role of interactions between central and peripheral systems in PD's pathogenesis, highlighting the need for a paradigm shift in PD research. The spotlight is now shifting as we explore beyond the central nervous system, discovering that peripheral changes such as inflammatory dysfunctions may predict the rate of disease progression and severity. However, the cellular mechanisms driving these immunity changes remain largely unknown. Despite over 200 years of research on PD, robust diagnostic or progression biomarkers and disease altering therapeutics are still lacking. Thus, understanding peripheral immune signatures could lead to earlier diagnosis and more effective treatments for PD. Here, we sought to define the transcriptomic alterations of the complete peripheral immune cell compartment by single-cell RNA- and T-cell receptor-sequencing with hopes of uncovering PD signatures and potential peripheral blood biomarkers. Following transcriptional profiling of 78 876 cells from 10 healthy controls and 14 PD donors, we observed five major classes of immune cell types; myeloid (monocytes, dendritic cells) and lymphoid (T, B, natural killer) cells from which we identified 38 cellular subtypes following bioinformatic re-clustering. Comparing immune cell subtypes and phenotypes between PD patients and healthy controls revealed notable features of PD: 1) a significant shift of classical CD14+ monocytes towards an activated CD14+/CD83+ state, 2) changes in lymphocyte subtypes abundance, including a significant decrease in CD4+ naive and mucosal-associated invariant T-cells subtypes, along with an increase in CD56+ natural killer cells, 3) the identification by T-cell receptor sequencing of several PD specific T-cell clones shared between multiple patients, suggesting the implication of common epitopes in PD pathogenesis, 4) a notable increase in the expression of activation signature genes, including the AP-1 stress-response transcription factor complex, across all PD cell types. This signal was not present in atypical Parkinsonism patients with multiple systems atrophy or progressive supranuclear palsy. Overall, we present a comprehensive atlas of peripheral blood mononuclear cells from control and PD patients which should serve as a tool to improve our understanding of the role the immune cell landscape plays in PD pathogenesis.

show abstract

“…The treatment of PD involves both pharmacological and non‐pharmacological interventions, with a combination of these typically resulting in better health outcomes and reduced disability. Exercise in various forms is accepted as one of the mainstays of treatment, and in recent years the importance of exercise in reducing PD symptoms, and even possibly slowing disease progression, has become increasingly appreciated 4–7 . Many different types of exercises have been investigated, including aerobic exercises like walking and treadmill exercise, strength interventions, balance and gait interventions, hydrotherapy, Pilates, dance, boxing, tai chi and other multimodal exercise combinations.…”

Section: Introductionmentioning

confidence: 99%

The ‘PD Warrior’ exercise programme improves motor outcomes and quality of life in patients with early Parkinson disease: results of a pilot study

Tucak,

Chih,

Mastaglia

et al. 2023

Internal Medicine Journal

View full text Add to dashboard Cite

Background‘PD Warrior’ (PDW) is a popular exercise program for Parkinson's disease; however, there are no published studies on the outcomes of the program.AimsTo investigate short‐term functional and quality of life (QoL) outcomes after the PDW 10‐week program in a pilot study of individuals with early Parkinson's Disease (PD).MethodsTwenty individuals with PD (Hoehn & Yahr 1–3) attending a hospital outpatient clinic were recruited into the PDW 10‐week program, comprising a weekly 1‐h supervised class complemented by an individualised daily home exercise program. Participants had the following assessments at baseline and after completion of the program: Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS‐UPDRS) Part III, timed up‐and‐go (TUG), 10‐m walk test (10mWT), 6‐min walking test (6MWT), balance tests, fine motor skills, 7‐day Parkinson's KinetiGraph (PKG) and PDQ‐39 QoL scale.ResultsSeventeen individuals completed the program. Significant improvements were observed in MDS‐UPDRS motor score (P = 0.019, d = 0.68, MCID 7); 6MWT distance (P < 0.001, d = 1.16); walking time during motor or cognitive dual tasking (P = 0.006, d = 0.77; P = 0.005, d = 0.79, respectively); and the PDQ‐39 emotional well‐being subdomain (P = 0.009; MCID 4.2); as well as improvements trending to significance in bradykinesia (P = 0.025, d = 0.73), 10mWT walking time (P = 0.023, d = 0.61) and borderline improvement in balance (P = 0.056, d = 0.50).ConclusionsThe outcomes of this study support the efficacy of the PDW program in individuals with early PD and provide justification for future trials and investigation of its effects.

show abstract

On Disease Modifying and Neuroprotective Treatments for Parkinson's Disease: Physical Exercise

Cited by 7 publications

References 40 publications

Functional neurological disorder, physical activity and exercise: What we know and what we can learn from comorbid disorders

Functional neurological disorder, physical activity and exercise: What we know and what we can learn from comorbid disorders

Mapping the peripheral immune landscape of Parkinson’s disease patients with single-cell sequencing

The ‘PD Warrior’ exercise programme improves motor outcomes and quality of life in patients with early Parkinson disease: results of a pilot study

Contact Info

Product

Resources

About